Individually Targeted Neuromodulation for Contamination-based OCD
Key facts
- Who runs it
- Mclean Hospital
- Where
- Belmont, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 1 Jul 2022
- Planned end
- 30 Jun 2024
- Type of study
- Interventional, 3 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- cTBS
- iTBS
- sham
- Record updated
- 15 March 2024
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- male or female age 18-55 years old
- DSM-5 diagnosis of OCD as primary presenting disorder
- CONTAM as the predominant symptom dimension (i.e., Dimension 4 (CONTAM symptoms) is the highest score on the Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS); participants with more than one Dimension as highest score will still be eligible as long as Dimension 4 is one of these)
- score of ≥ 8 on Dimension 4 of the D-YBOCS
- taking no psychiatric medications or on a stable dose of an SSRI, clomipramine, SNRI, or second generation antipsychotic for at least 4 weeks prior to enrollment. Use of PRN benzodiazepines will be permitted as long as the dose/usage has not changed significantly leading up to enrollment. No medication changes will be permitted during the study
- have not initiated a new course of exposure and response prevention (ERP) therapy within 4 weeks of enrollment (ongoing ERP will be permitted if initiated more than 8 weeks before enrollment)
Who cannot take part
- positive urine drug screen (other than prescribed benzodiazepines)
- active suicidal ideation over the week prior to screening (as indicated by answering yes to questions 1 or 2 on the C-SSRS)
- use of psychiatric medications other than permitted above
- substance use disorder in the last 3 months (with the exception of nicotine)
- history of schizophrenia, bipolar disorder, autism, Tourette's syndrome (current and past history of depressive, anxiety, and eating disorders permitted as long as OCD is considered the primary disorder)
- history of traumatic brain injury, seizure disorder, neurodegenerative disease, or other organic brain disease
- pregnancy or lactating
- contraindication to MRI scanning or TMS
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Obsessive-compulsive disorder
This trial is currently available in United States.
- McLean HospitalBelmont, United StatesContact: Brian P Brennan, MDTaking people
About the trial
What the trial wants to find out
Patients with obsessive-compulsive disorder (OCD) experience a wide array of different types of obsessions and compulsions. However, current treatments for OCD employ a "one size fits all" approach and are used for all patients regardless of symptom type. In this project, the investigators propose to investigate whether a novel method of transcranial magnetic stimulation specifically reduces contamination/washing symptoms - one of the most common types of OCD.
The 3 groups in the trial
- cTBSTreatment being tested
continuous TBS to right MFG
- iTBSTreatment being tested
intermittent TBS to right MFG
- shamSham treatment, for comparison
sham stimulation to right MFG
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Individually Targeted Neuromodulation for Contamination-based Obsessive-compulsive Disorder
- Criteria questions
- Built from NCT05048251, who can take part
- Record updated
- 15 March 2024